Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy
Boehringer Ingelheim has taken legal steps giving it the lead role in further development of a long-lasting, inhalation gene therapy for cystic fibrosis (CF), called BI 3720931, that stems from a public-private research effort begun in 2018. The 2018 agreement brought together Boehringer, the U.K. Cystic Fibrosis…